Impact of Probiotics for Reducing Infections in Veterans: The IMPROVE Study

Completed · Phase 2 · Has a placebo group

Conditions studied: Anti-biotic Resistance

In brief

The investigators have two hypotheses: (1) The probiotic L. rhamnosus HN001, when compared to placebo, will reduce S. aureus nasal colonization when taken for four weeks. (2) The probiotic L. rhamnosus HN001, when compared to placebo, will reduce S. aureus gastrointestinal colonization when taken for four weeks.

Key facts

Study ID

NCT01321606

Run by

VA Office of Research and Development

People needed

113

Starts

2011-10-01

Expected to finish

2015-12-01

Last updated by the study team

2018-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Colonized at nasal or gastrointestinal source by S. aureus including MRSA
• Age 18 years or older
• Able to take oral medications
• Able to provide informed consent

You may not qualify if…

• Uncontrolled psychiatric illness
• On a decolonization protocol for MRSA (e.g mupirocin, tea tree oil)
• Current involvement in another investigational trial
• Pregnancy
• Persistent diarrhea (> 3 loose stools per day for at least 2 days)
• Active infection with S.aureus or MRSA

Where it is running

• William S. Middleton Memorial Veterans Hospital, Madison, WI — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.